Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, presented data today at the T-cell ...
Earlier in June 2026, Cullinan Therapeutics reported updated Phase 1 data showing CLN-978 and velinotamig produced strong clinical responses and favorable safety in treatment-refractory rheumatoid ...
Deck Bio, a biotechnology company advancing multi-pMHC targeted T cell engagers for solid tumors, today announced its participation in the 8th T-Cell Engager Therapeutics Summit and the BIO ...
CX-904 was the first masked T-cell engager CytomX Therapeutics took into the clinic. (stocknshares/iStock/Getty Images Plus) Amgen and CytomX Therapeutics have kicked ...
Advancing the Development of Novel Targets, Safe, & Effective Multi-Specific Immune Cell Engagers for Solid & Liquid Tumors in the Clinic With a whopping 7 approvals in the last two years, the field ...
Data Demonstrate High Procedural Success in Late-Breaking Trials Session at the European Association for Cardio-Thoracic Surgery Annual Meeting MINNEAPOLIS – Medtronic, Inc. today announced promising ...
Join your colleagues from the likes of Apexigen, Regeneron Pharmaceuticals, Genentech, Roche, Amgen, Boehringer Ingelheim and many more at the most comprehensive cell engager event, leaving no stone ...
Findings highlight RedTail’s potential to overcome historical limitations of T-cell engagers in solid tumors through tumor-specific, localized expression SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results